Marker Therapeutics' Losses Mount Amid R&D Surge, Cash Dwindles

TL;DR

**MRKR is burning cash at an alarming rate with dwindling grant income, making it a high-risk bet on future financing and clinical success.**

AI Summary

Marker Therapeutics, Inc. (MRKR) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $8,461,748, a 84.5% increase from $4,585,499 in the same period of 2024. This was primarily driven by a 49% surge in research and development expenses to $7,312,481 from $4,910,446, and a new loss of $453,135 on early termination of a vendor agreement. Total revenues, primarily from grant income, decreased by 49.8% to $1,210,288 from $2,413,297. Cash and cash equivalents declined to $10,461,971 as of June 30, 2025, from $19,192,440 at December 31, 2024. The company secured $4.5 million in net proceeds from an ATM offering in July 2025 and received several grants, including $1.6 million from a CPRIT Pancreatic Grant. Despite these efforts, management anticipates funding operating expenses only into the second quarter of 2026, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

Marker Therapeutics' escalating net losses and declining cash position are critical for investors, signaling increased financial risk and potential dilution. The company's reliance on grant funding and ATM offerings for liquidity, coupled with a projected cash runway only into Q2 2026, puts pressure on its ability to advance its immuno-oncology pipeline, including MT-601 and MT-401. This financial strain could impact its competitive standing against larger biotech firms with more robust funding, potentially delaying clinical trials or forcing unfavorable financing terms. Employees and customers face uncertainty regarding the long-term viability of the company and its promising T-cell therapies.

Risk Assessment

Risk Level: high — The company's net loss increased by 84.5% to $8,461,748 for the six months ended June 30, 2025, compared to the prior year. Cash and cash equivalents decreased by 45.5% from $19,192,440 at December 31, 2024, to $10,461,971 at June 30, 2025. Management explicitly states that these factors raise "substantial doubt regarding the Company's ability to continue as a going concern," with a projected cash runway only into the second quarter of 2026.

Analyst Insight

Investors should exercise extreme caution and consider the significant going concern risk. Monitor closely for successful capital raises beyond the July 2025 ATM offering and any positive clinical trial data that could attract further investment, as the current financial trajectory is unsustainable without substantial new funding.

Financial Highlights

debt To Equity

0.41

revenue

$1,210,288

operating Margin

-732.5%

total Assets

$14,767,870

total Debt

$4,277,477

net Income

-$8,461,748

eps

-$0.67

gross Margin

N/A

cash Position

$10,461,971

revenue Growth

-49.8%

Revenue Breakdown

Key Numbers

• $8.46M — Net Loss (Increased by 84.5% for six months ended June 30, 2025, from $4.59M in 2024)
• $1.21M — Total Revenues (Decreased by 49.8% for six months ended June 30, 2025, from $2.41M in 2024)
• $7.31M — Research and Development Expenses (Increased by 49% for six months ended June 30, 2025, from $4.91M in 2024)
• $10.46M — Cash and Cash Equivalents (As of June 30, 2025, down from $19.19M at Dec 31, 2024)
• $4.5M — Net Proceeds from ATM (Received in July 2025, after agent commissions)
• Q2 2026 — Projected Cash Runway (Anticipated funding period for operating expenses)
• 12,938,910 — Common Stock Outstanding (As of August 4, 2025)
• $455.48M — Accumulated Deficit (As of June 30, 2025, up from $447.02M at Dec 31, 2024)

Key Players & Entities

• Marker Therapeutics, Inc. (company) — clinical-stage immuno-oncology company
• H.C. Wainwright & Co. LLC (company) — agent for At The Market Offering Agreement
• Cellipont Bioservices (company) — Contract Development and Manufacturing Organization for MT-601
• Baylor College of Medicine (company) — supplier of MT-601
• Cancer Prevention and Research Institute of Texas (regulator) — grant provider (CPRIT)
• U.S. Food and Drug Administration (regulator) — grant provider (FDA)
• National Institutes of Health (regulator) — grant provider (NIH SBIR program)
• MT-601 (product) — lead Multi-Antigen Recognizing (MAR)-T cell therapy
• MT-401 (product) — product candidate for Acute Myeloid Leukemia
• $4.5 million (dollar_amount) — net proceeds from ATM offering in July 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management anticipates funding operating expenses only into the second quarter of 2026, raising substantial doubt about the company's ability to continue as a going concern. This is exacerbated by an 84.5% increase in net loss to $8.46 million for the six months ended June 30, 2025.
• Declining Cash Position [high — financial]: Cash and cash equivalents decreased to $10.46 million as of June 30, 2025, from $19.19 million at December 31, 2024. This significant burn rate, coupled with a 49.8% decrease in total revenues, highlights the need for continued financing.
• Increased R&D Expenses [medium — operational]: Research and development expenses surged by 49% to $7.31 million for the six months ended June 30, 2025, from $4.91 million in the prior year. While indicative of investment in pipeline development, this increase contributes significantly to the widening net loss.
• Vendor Agreement Termination [low — operational]: The company incurred a new loss of $453,135 due to the early termination of a vendor agreement during the six months ended June 30, 2025. This represents an unbudgeted expense that impacted profitability.
• Reliance on Grant Income [medium — financial]: Total revenues, primarily consisting of grant income, decreased by 49.8% to $1.21 million for the six months ended June 30, 2025. This reliance on grant funding introduces revenue volatility and uncertainty.

Industry Context

Marker Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel immunotherapies. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on securing substantial funding through equity offerings, partnerships, or grants to advance drug candidates through clinical trials.

Regulatory Implications

As a clinical-stage biotechnology company, Marker Therapeutics is subject to stringent regulatory oversight by bodies like the FDA. Delays in clinical trials, adverse safety findings, or failure to meet regulatory endpoints can significantly impact development timelines and the company's ability to achieve commercialization, posing a direct risk to its financial viability.

What Investors Should Do

1. Monitor cash burn and runway closely.
2. Evaluate the progress of R&D programs.
3. Assess the sustainability of grant funding.
4. Consider the impact of potential future equity dilution.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported a net loss of $8.46 million and cash and cash equivalents of $10.46 million, highlighting a deteriorating financial position and a projected cash runway into Q2 2026.
• 2025-07-01: ATM Offering — Secured $4.5 million in net proceeds, providing a temporary cash infusion to mitigate the going concern issue.
• 2025-08-04: Common Stock Outstanding — 12,938,910 shares outstanding, indicating potential dilution from future equity offerings.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any net gains. It represents a deficit in retained earnings. (Marker Therapeutics has a substantial accumulated deficit of $455.48 million as of June 30, 2025, underscoring its history of unprofitability.)

Going concern

An accounting assumption that a company will continue to operate for the foreseeable future. If doubt exists, it must be disclosed. (Management's acknowledgment of doubt about the company's ability to continue as a going concern into Q2 2026 is a critical warning sign for investors.)

ATM offering

At-the-market offering, where a company sells stock over time through one or more stock exchanges at prevailing market prices. (The company utilized an ATM offering in July 2025 to raise $4.5 million, a common strategy for companies needing flexible capital raises.)

Grant income

Revenue recognized from grants, typically awarded by government agencies or foundations for specific research or development purposes. (This is the primary source of revenue for Marker Therapeutics, and its significant decline (-49.8%) is a major factor in the company's financial challenges.)

Year-Over-Year Comparison

Compared to the six months ended June 30, 2024, Marker Therapeutics has seen a dramatic increase in its net loss, up 84.5% to $8.46 million, primarily due to a 49% surge in R&D expenses to $7.31 million. Total revenues have plummeted by 49.8% to $1.21 million, largely driven by a decrease in grant income. The company's cash position has also significantly weakened, falling from $19.19 million at year-end 2024 to $10.46 million by mid-2025, intensifying concerns about its ability to continue as a going concern.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
• $250,000 — Corporation ("FDIC") insured limits of $250,000. As of June 30, 2025, the Company had a

Filing Documents

• mrkr-20250630x10q.htm (10-Q) — 1221KB
• mrkr-20250630xex31d1.htm (EX-31.1) — 13KB
• mrkr-20250630xex31d2.htm (EX-31.2) — 13KB
• mrkr-20250630xex32d1.htm (EX-32.1) — 8KB
• mrkr-20250630xex32d2.htm (EX-32.2) — 8KB
• mrkr-20250630x10q001.jpg (GRAPHIC) — 12KB
• mrkr-20250630x10q002.jpg (GRAPHIC) — 40KB
• mrkr-20250630x10q003.jpg (GRAPHIC) — 28KB
• 0001410578-25-001826.txt ( ) — 5269KB
• mrkr-20250630.xsd (EX-101.SCH) — 38KB
• mrkr-20250630_cal.xml (EX-101.CAL) — 23KB
• mrkr-20250630_def.xml (EX-101.DEF) — 149KB
• mrkr-20250630_lab.xml (EX-101.LAB) — 299KB
• mrkr-20250630_pre.xml (EX-101.PRE) — 233KB
• mrkr-20250630x10q_htm.xml (XML) — 763KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets As of June 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 28 Item 4.

Controls and Procedures

Controls and Procedures. 28

– OTHER INFORMATION

PART II – OTHER INFORMATION 29 Item 1. Legal Proceedings. 29 Item 1A. Risk Factors. 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 29 Item 3. Defaults Upon Senior Securities. 29 Item 4. Mine Safety Disclosure. 29 Item 5. Other Information. 29 Item 6. Exhibits. 30

Signatures

Signatures 32 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statement s

Item 1. Financial Statement s MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) June 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 10,461,971 $ 19,192,440 Restricted cash 1,352,975 — Prepaid expenses and deposits 1,278,589 483,717 Other receivables 1,674,335 2,346,703 Total current assets 14,767,870 22,022,860 Total assets $ 14,767,870 $ 22,022,860 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 2,267,871 $ 1,753,954 Related party payable 656,631 1,710,500 Deferred revenue 1,352,975 — Total current liabilities 4,277,477 3,464,454 Total liabilities 4,277,477 3,464,454 Stockholders' equity: Preferred stock, $ 0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at June 30, 2025 and December 31, 2024 , respectively — — Common stock, $ 0.001 par value, 30 million shares authorized, 11.3 million and 10.7 million shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively (see Note 8) 11,313 10,708 Additional paid-in capital 465,958,006 465,564,876 Accumulated deficit ( 455,478,926 ) ( 447,017,178 ) Total stockholders' equity 10,490,393 18,558,406 Total liabilities and stockholders' equity $ 14,767,870 $ 22,022,860 See accompanying notes to these unaudited condensed consolidated financial statements. 1 Table of Contents MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended For the Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenues: Grant income $ 861,184 $ 1,169,236 $ 1,210,288 $ 2,413,297 Total revenues 861,184 1,169,236 1,210,288 2,413,297 Operating expenses: Research and development 4,177,054 2,335,430 7,312,481 4,910,446 General and administrative 945,163 1,141,8

View Full Filing

View this 10-Q filing on SEC EDGAR